

Neurologists' Awareness and Preparedness on Prion Diseases in Korea

Jae-Won Jang, M.D.*,
Young Ho Park, M.D.*,
Jae Sung Lim, M.D.†,
Soo Chul Park, M.D.‡,
Hae-Kwan Cheong, M.D.§,
Jung E. Kim, M.D.*,
SangYun Kim, M.D.*

Department of Neurology*, Seoul National University Bundang Hospital, Seongnam;
Department of Neurology†, Seoul National University Boramae Hospital, Seoul;
Department of Neurology‡, Yonsei University Severance Hospital, Seoul; Department of Social and Preventive Medicine§, Sungkyunkwan University School of Medicine, Suwon, Korea

Received: February 5, 2013
Revision received: March 28, 2013
Accepted: March 28, 2013

Address for correspondence

SangYun Kim, M.D.
Clinical Neuroscience Center, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 463-707, Korea
Tel: +82-31-787-7462
Fax: +82-31-719-6815
E-mail: neuroksy@snu.ac.kr

* This study was supported by Centers for Disease Control and Prevention, Ministry of Health and Welfare, Republic of Korea (2012E21000100).

Background: Creutzfeldt-Jakob disease (CJD) is very rare human prion disease. But, neurologists take a key role in diagnosis, surveillance and management of the cases because of its complexity and difficulty in diagnosis of the disease. The aim of this study is to investigate the level of awareness and preparedness of Korean neurologists on this rare disease. **Methods:** Survey sheets of self-administered questionnaire were given to Korean neurologists who participated in the 31st Annual Meeting of the Korean Neurological Association. Data from 133 respondents were conducted by descriptive analysis. **Results:** Their answers were as follows: About 62% of neurologists have experienced patients of CJD. Forty-four percent of the patients were confirmed by brain biopsy. Most of neurologists (44%) were not confident to diagnose CJD and the reason why they felt hard to diagnose was due to the variable initial clinical manifestations (45.1%) and the lack of clinical experience (51.9%). Heidenheim variant CJD, proteinase sensitive prionopathy, molecular subtypes of sporadic CJD, diagnostic criteria was not familiar term to Korean neurologists (76.7%, 53.4%, 58.6%, and 62.4% respectively). Opinion for the most useful diagnostic tool was brain MRI (45.1%), CSF 14-3-3 protein (30.1%), typical EEG finding (36.8%) and gene (PRNP) test (42.9%). And they consider none of them are specific for the diagnosis of CJD (89.5%, 73.7%, 83.5%, 91.7%, respectively). Most of the neurologist in this survey answered that the opportunity for education of CJD should be increased (67.7%). **Conclusions:** Most of neurologists have encountered CJD patients although it is very rare disease. Some of the important and fundamental concepts of CJD were not correctly recognized to Korean neurologists, necessitating a persistent support for updating knowledge and information.

Key Words: Creutzfeldt-Jakob disease, Survey, Neurologists, Knowledge attitude and practice (KAP)

INTRODUCTION

Creutzfeldt-Jakob disease (CJD) is the most frequent human prion disease, although it is rare. The vast majority of CJD cases are sporadic (about 85%) and calculated prevalence of it is approximately 1-1.5 cases per one million population a year with a worldwide distribution [1]. In Korea, the social anxiety increased a lot regarding import of beef from U.S. in 2008. As a result, CJD including variant CJD has be-

come the center of public interest in Korea. It requires professional experience in the course of diagnosis, and neurologist plays a critical role in the disease surveillance as well as in the diagnosis and management of it. The registration rate and accuracy of diagnosis in Korea are still very low compared to that of developed countries. This study was aimed to investigate the level of awareness, clinical experience and preparedness of Korean neurologists who would encounter the patient of CJD at first place. This study would be used as basic data

for improving Korean surveillance system and also for better caring and educational system.

METHODS

The survey was performed for the participants on the 31st Annual Meeting of the Koran Neurological Association in April 2012. Total participants of the meeting were 688 (442 specialists, 246 residents) and 133 neurologists voluntarily responded survey among them. A survey was considered to be the most efficient and accurate measure to evaluate neurologists' current knowledge and practice regarding CJD. The survey questions were developed with 29-item questionnaire

Table 1. Demographics of neurologists (N = 133)

	N	(%)
Age		
20s	20	15.0
30s	87	65.4
40s	21	15.8
50s	5	3.8
Specialty of Neurology		
Specialists	83	61.7
Residents	51	38.3
4th grade	24	18.0
3rd grade	16	12.0
2nd grade	10	7.5
Types of hospitals		
University hospital	101	75.9
General hospital	7	5.3
Secondary hospital	6	4.5
Army medical officer/Public health doctor	7	5.3
Others	1	0.8
No response	11	8.3
The hospital location		
City		
Seoul	71	53.4
Busan	8	6.0
Daegu	4	3.0
Incheon	5	3.8
Gwangju	1	0.8
Daejeon	3	2.3
Ulsan	2	1.5
Province		
Gyeonggi-do	23	17.3
Gyeongsangnam-do	2	1.5
Gyeongsangbuk-do	2	1.5
Jeollanam-do	3	2.3
Jeollabuk-do	3	2.3
Chungcheongnam-do	4	3.0
Chungcheongbuk-do	1	0.8
Jeju-do	1	0.8
Total	133	100.0

(appendix) covered 5 categories which were demographics of neurologists, clinical experience on CJD, diagnosis, terminology and educational/reporting system. It was self-administrated survey and after reviewing of collected data, descriptive statistics, such as percentages and sample size were used to describe how neurologists responded to specific questions. Most of the data are analyzed according to specialty of neurology (resident or specialist of neurology).

RESULTS

Demographics of the participating neurologists on this survey

Among the neurologists who participated on the 31st Annual Meeting of the Koran Neurological Association in April 2012, 133 members replied on our survey. Eighty-three members were specialists of neurology and 51 members were residents of neurology. Age range of participants distributed from 20s to 50s. About 75% of respondents worked for university hospital. The most frequent city they worked in was Seoul (53.4%) and Gyeonggi-do held the second rank (17.3%) (Table 1).

Clinical experience on CJD

On this survey, 62.4% of the neurologists had cared CJD suspected patients directly and 15% had observed diagnosed cases in their hospital although they had not cared in person, and 19.5 % had not cared CJD suspected patients before (Fig.




Fig. 1. Personal experience of CJD patients.

1). The percentage of the neurologists who made clinical diagnosis of CJD were 48% (n = 57) and who made confirmatory diagnosis by brain biopsy or autopsy were 44% (n = 52) (Fig. 2). Among respondents, 27.1% of them said that CJD might occur more than 40 cases a year and 24.8% said that 10 to 19 cases might occur in Korea. Among 27.8% of neurologists answered that clinically diagnosed CJD might be less than 10 cases per year and 24.8% replied 10 to 19 cases a year and just 16.5% considered more than 40 cases a year in Korea (Table 2).

Diagnosis

Whereas 48% of neurologists were confident in the diagnosis of CJD clinically unless it was atypical case, 44% were not confident. The Lack of clinical experience and limited information were the most difficult problems regarding the diagnosis of CJD (51.9%) and various clinical presentations in the early stage of disease were also playing a role as an obstacle for correct diagnosis (45.1%). Respondents thought that most important diagnostic clues for suspecting CJD were




Fig. 2. The types of diagnosis.

rapid progressive cognitive decline (86.5%) and myoclonus (10.5%). Regarding useful diagnostic tools in order of importance were suggested that clinical findings (66.2%), brain MRI (45.1%), CSF 14-3-3 protein (30.1%), EEG (36.8%) and gene (PRNP) test (42.9%) in order. When positive finding of CSF 14-3-3 protein is combined with rapidly progressive dementia, 31.6% of respondents answered that the possibility of CJD is about 60 to 79% and 28.6% answered as 40 to 59%. If myoclonus is added to them, 40.8% of neurologists regarded the possibility of CJD is increased as high as 80 to 100% and 28.6% regarded as 60 to 79%. They responded that CSF 14-3-3 protein could be negative in 63.2% and 22.6% of them thought that initially it could be negative but it would be converted into positive in the course of disease. About 31% of neurologists estimated positive predictive values of CSF 14-3-3 protein in Korea might be 40 to 59%, 19.5% of them as 60 to 79% and 17.3% of them as 20 to 39% respectively. With regard to the question about the specificity of diagnostic tools, positive findings of clinical signs, specific brain MRI findings, CSF 14-3-3 protein and EEG periodic sharp wave complex were thought to be found in other diseases also (89.5%, 73.7%, 83.5%, 91.7% respectively). About 50% of neurologists answered that brain biopsy or autopsy was necessary just in case of confusion in the diagnosis of CJD whereas 45.1% replied that it was necessary although it was certain as CJD clinically. Similarly to this, 52.6% of respondents said they would transfer just in case of confusion in the diagnosis of CJD for brain biopsy and 46.6% answered that they would definitely persuade caregiver for brain biopsy. Regarding transferring CJD suspected patients to superior hospitals for definite diagnosis or second opinion, 35.3% said they had transferred most of the patients for second opinion, 32.3% said that they hadn't

Table 2. Awareness of national status of prion diseases in Korea

	How many CJD patients would occur in a year?			How many CJD patients would be diagnosed in a year?		
	Resident (%)	Specialist (%)	Total (%)	Resident (%)	Specialist (%)	Total (%)
< 10	4 (7.8)	10 (12.2)	14 (10.5)	12 (23.5)	25 (30.5)	37 (27.8)
10-19	15 (29.4)	18 (22.0)	33 (24.8)	12 (23.5)	21 (25.6)	33 (24.8)
20-29	8 (15.7)	12 (14.6)	20 (15.0)	8 (15.7)	12 (14.6)	20 (15.0)
30-39	5 (9.8)	10 (12.2)	15 (11.3)	2 (3.9)	6 (7.3)	8 (6.0)
≥ 40	11 (21.6)	25 (30.5)	36 (27.1)	9 (17.6)	13 (15.9)	22 (16.5)
I don't know	8 (15.7)	5 (6.1)	13 (9.8)	7 (13.7)	5 (6.1)	12 (9.0)
No response	0 (0)	2 (2.4)	2 (1.5)	1 (2.0)	0 (0)	1 (0.8)
Total	51 (100)	82 (100)	133 (100.0)	51 (100)	82 (100)	133 (100.0)

Table 3. Self-evaluation of capacity of diagnosis and management for prion diseases

Questions related to diagnosis	Response	All survey (n = 133)		
		Resident (%)	Specialist (%)	Total (%)
Q1. Are you confident in the diagnosis of CJD?	1) Yes 2) Yes unless it is specific case 3) No.	0 (0) 19 (37.3) 32 (62.7)	11 (13.4) 45 (54.9) 23 (31.7)	11 (8) 64 (48) 58 (44)
Q2. What do you think most difficult problem in the diagnosis of CJD?	1) Various clinical presentation in the early stage 2) Lack of clinical experience & limited information 3) Others	21 (41.2) 30 (58.8) 0 (0)	39 (47.6) 39 (47.6) 4 (4.9)	60 (45.1) 69 (51.9) 4 (3.0)
Q3. What do you think the most important clinical sign is in the diagnosis of CJD patient?	1) Myoclonus 2) Rapid progressive cognitive decline 3) Visual symptom 4) Cerebellar symptom 5) Others	8 (15.7) 42 (82.4) 0 (0) 1 (2.0) 0 (0)	6 (7.3) 73 (89.0) 0 (0) 1 (1.2) 2 (2.4)	14 (10.5) 115 (86.5) 0 (0) 2 (1.5) 2 (1.5)
Q4. Please select most useful diagnostic tools among items suggested as examples	1) Clinical findings 2) Brain MRI (including diffusion weighted image), 3) CSF 14-3-3 protein 4) EEG 5) Gene test (PRNP mutation or codon 129 type)	34 (66.7) 4 (7.8) 9 (17.6) 0 (0) 2 (3.9)	54 (65.9) 9 (11.0) 6 (7.3) 1 (1.2) 12 (14.6)	88 (66.2) 13 (9.8) 15 (11.3) 1 (0.8) 14 (10.5)
Q7. What do you think about CSF 14-3-3 protein in CSF regarding CJD?	1) It is always positive in CJD patients 2) It can be negative in CJD patients although it is rare 3) Initially it could be negative → positive later 4) I don't know 5) No response	3 (5.9) 37 (72.5) 8 (15.7) 3 (5.9) 0 (0)	7 (8.5) 47 (57.3) 22 (26.8) 5 (6.1) 1 (1.2)	10 (7.5) 84 (63.2) 30 (22.6) 8 (6.0) 1 (0.8)
Q8. How many patients would be diagnosed as CJD among the patients who revealed positivity in CSF 14-3-3 protein of CSF in Korea?	1) < 20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don't know 7) No response	4 (7.8) 9 (17.6) 19 (37.3) 10 (19.6) 0 (0) 9 (17.6) 0 (0)	11 (13.4) 14 (17.1) 22 (26.8) 16 (19.5) 5 (6.1) 13 (15.9) 1 (1.2)	15 (11.3) 23 (17.3) 41 (30.8) 26 (19.5) 5 (3.8) 22 (16.5) 1 (0.8)
Q10. Do you think brain biopsy or autopsy is necessary for definite diagnosis of CJD suspected patient?	1) It is necessary although it is certain clinically. 2) It is necessary just in case of diagnostic confusion 3) It is not necessary	25 (49.0) 25 (49.0) 1 (2.0)	35 (42.7) 44 (53.7) 3 (3.7)	60 (45.1) 69 (51.9) 4 (3.0)
Q11. Would you transfer your CJD suspected patient for brain biopsy if there is a specialized hospital for brain biopsy in Korea?	1) Persuade caregiver for brain biopsy or autopsy 2) Transfer just in case of diagnostic confusion 3) It is not necessary	22 (43.1) 29 (56.9) 0 (0)	40 (48.8) 41 (50.0) 1 (1.2)	62 (46.6) 70 (52.6) 1 (0.8)
Q12. Have you ever transferred your CJD suspected patient(s) to superior hospital for seeking definite diagnosis or second opinion?	1) transferred most of the patients for second opinion 2) transferred just in case of diagnostic confusion 3) haven't transferred unless caregiver wanted to 4) No response	15 (29.4) 15 (29.4) 21 (41.2) 0 (0)	32 (39.0) 26 (31.7) 22 (26.8) 2 (2.4)	47 (35.3) 41 (30.8) 43 (32.3) 2 (1.5)
Q5. What do you think about the possibility of CJD when patient show rapidly progressive dementia, myoclonus and positive 4-3-3 protein in CSF?	1) < 20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don't know	2 (3.9) 4 (7.8) 12 (23.5) 17 (33.3) 15 (29.4) 1 (2.0)	1 (1.2) 2 (2.4) 13 (15.9) 21 (25.6) 39 (47.6) 6 (7.3)	3 (2.3) 6 (4.5) 25 (18.8) 38 (28.6) 54 (40.6) 7 (5.3)
Q6. What do you think about the possibility of CJD when patient show rapidly progressive dementia and positive 4-3-3 protein in CSF?		2 (3.9) 11 (21.6) 15 (29.4) 17 (33.3) 4 (7.8) 2 (3.9)	2 (2.4) 15 (18.3) 23 (28.0) 25 (30.5) 9 (11.0) 7 (8.5)	4 (3.0) 26 (19.5) 38 (28.6) 42 (31.6) 13 (9.8) 9 (6.8)
Q9. What is your opinion about the specificity of diagnostic tools?				
1. Rapidly progressive dementia	1) Only in CJD 2) Other diseases 3) I don't know 4) No response	1 (2.0) 50 (98.0) 0 (0) 0 (0)	12 (14.6) 69 (84.1) 1 (1.2) 0 (0)	13 (9.8) 119 (89.5) 1 (0.8) 0 (0)
2. MRI finding		11 (21.6) 39 (76.5) 1 (2.0) 0 (0)	20 (24.4) 59 (72.0) 2 (2.4) 1 (1.2)	31 (23.3) 98 (73.7) 3 (2.3) 1 (0.8)
3. CSF 14-3-3(+)		7 (13.7) 42 (82.4) 2 (3.9) (0)	8 (9.8) 69 (84.1) 3 (3.7) 2 (2.4)	15 (11.1) 111 (83.5) 5 (3.8) 2 (1.5)
4. EEG finding (PSWC)		4 (7.8) 46 (90.2) 1 (2.0) 0 (0)	4 (4.9) 76 (92.7) 1 (1.2) 1 (1.2)	31 (23.3) 98 (73.7) 3 (2.3) 2 (1.5)

transferred unless caregiver wanted to and 30.8% replied just in case of confusion in the diagnosis (Table 3).

Terminology and awareness

About the terminologies related to CJD, most of the respondents answered that they know well or know a little at least about sporadic CJD (sCJD), variant CJD (vCJD), iatrogenic CJD (iCJD) and familiar CJD (fCJD) (49.6%, 41.4%, 43.6%, 39.8% respectively). Regarding diagnostic criteria of sCJD by National CJD surveillance, Heidenheim variant CJD, 6 molecular subtypes of sCJD, PSP_r (proteinase sensitive prionopathy)/VPSP (variably PSP_r), and Heidenheim variant CJD, small proportion of them answered that they know well or know a little at least about those disease entities or criteria (37.6%, 41.4%, 45.9%, 21.8% respectively) (Fig. 3). Many re-

spondents replied that sCJD, iCJD and fCJD actually had occurred in Korea before (94.7%, 75.2%, 44.4% respectively). However, only 49.6% thought that vCJD had not occurred and most of neurologists said they didn't know whether PSP_r, GSS, FFI, or sFI occurred or not in Korea (50.4%, 60.2%, 50.4%, 63.2% respectively) (Fig. 4).

About 8.5% of neurologists haven't used terms "human mad cow disease" to explain sCJD but 18.8% had used it. The 60.9% of respondents said that term should not be used but 36.8% replied that it was not proper but it could be used to explain sCJD. Most of the neurologists (66.2%) had been asked about medical issues related to CJD and they are general public (33.1%), paramedics (21%) and doctors of other specialty (20%) (Table 4).




Fig. 3. Familiarity with terminology related to CJD.




Fig. 4. Awareness of occurrence of each disease in Korea.

Table 4. Terminology and awareness

Questions	Response	All survey (n = 133)		
		Resident (%)	Specialist (%)	Total (%)
Q3. Have you ever used the term "Human mad cow disease" when you explain sporadic CJD?	1) Yes I have frequently	1 (2.0)	0 (0)	1 (0.8)
	2) Yes I have a few times	9 (17.6)	16 (19.5)	25 (18.8)
	3) No. I haven't.	41 (80.4)	66 (80.5)	107 (80.5)
Q4. Do you think the term "Human mad cow disease" is proper for explaining sporadic CJD?	1) Yes. It is proper	1 (2.0)	0 (0)	1 (0.8)
	2) No. But it can be used.	20 (39.2)	29 (35.4)	49 (36.8)
	3) No. It should not be used.	29 (56.9)	52 (63.4)	81 (60.9)
	4) No response	1 (2)	1 (1.2)	2 (1.5)
Q5. Have you ever been asked about the medical questions regarding CJD from others?	1) No.	26 (51.0)	19 (23.2)	45 (33.8)
	2) Yes.	25 (49.0)	63 (76.8)	88 (66.2)
Q6. Who asked you?	1) Other neurologists.	1 (2.0)	2 (2.4)	3 (2.3)
	2) Doctors of other specialty.	5 (9.8)	15 (18.3)	20 (15.0)
	3) Paramedics	2 (3.9)	19 (23.3)	21 (15.8)
	4) General public	17 (33.3)	27 (32.9)	44 (33.1)
	5) Never asked	26 (51.0)	19 (23.2)	45 (33.8)

Table 5. Educational/reporting system

Questions	Response	All survey (n = 133)		
		Resident (%)	Specialist (%)	Total (%)
Q1. Do you know the reporting system of suspected CJD patient to public health center?	1) Yes	18 (35.3)	28 (34.1)	46 (34.6)
	2) I've heard but don't know well	26 (51.0)	46 (56.1)	72 (54.1)
	3) I've never heard of it	7 (13.7)	8 (9.8)	15 (11.3)
Q2. How many times have you participated in the lecture or educational program related to CJD (or prionopathy)?	1) ≥ 3	5 (9.8)	27 (32.9)	32 (24.1)
	2) 1-2	24 (47.1)	46 (56.1)	70 (52.6)
	3) I've never participated in it.	22 (43.1)	7 (8.5)	29 (21.8)
Q3. Do you think educational opportunity for neurologists regarding CJD (or prionopathy) should be increased?	1) Yes.	40 (78.4)	50 (61.0)	90 (67.7)
	2) It is still enough.	11 (21.6)	30 (36.6)	41 (30.8)
	3) It is not necessary anymore	0 (0)	1 (1.2)	1 (0.8)
	4) No response		1 (1.2)	1 (0.8)
Q4. Would you participate in the educational program for CJD (or prionopathy) if it would be held in the future?	1) Yes.	12 (23.5)	19 (23.2)	31 (23.3)
	2) Participate as far as circumstances permit.	37 (72.5)	60 (73.2)	97 (72.9)
	3) No	2 (3.9)	2 (2.4)	4 (3.0)
	4) No response	0 (0)	1 (1.2)	1 (0.8)
Q5. Have you ever heard of the partial supporting system for medical expenses of CJD patients as rare and incurable disease?	1) Yes	8 (15.7)	14 (17.1)	22 (16.5)
	2) I've heard but don't know well	21 (41.2)	29 (35.4)	50 (37.4)
	3) I've never heard of it	22 (43.1)	38 (46.3)	60 (45.1)
	4) No response	0 (0)	1 (1.2)	1 (0.8)

Educational/reporting system

About 44% of neurologists on this survey had heard of the reporting system of suspected CJD patient to public health center but don't know well about it, 34.1% are well aware of it and 11.3% said that they never heard of it. Most of the respondents had participated in the lecture or educational programs related to CJD 1 to 2 times (52.6%) and 24.1% participated more than 3 times but 21.8% never had chance to participated in them. About the question asking the necessity of increasing educational opportunity for neurologists, 67.7% of respondents said "yes" but 30.8% of them thought it was still enough. About 72.9% of respondent replied that they would participate in the educational program as far as circumstances permit and 23.3% said they would participate for sure. Regarding partial economical supporting system for medical expenses of CJD patients as rare and incurable disease, 45.1% of respondents said that they had never heard of that and 37.6% had heard of it but don't know well and the proportion of the respondents who knew about it was as low as 16.5% (Table 5).

DISCUSSION

According to the reported incidence of CJD, it seems to be

50 to 75 patients per year in Korea. Although the incidence is very low, it is important as a fatal disease without cure and should be considered as first differential diagnosis of patients with rapidly progressive dementia. In 2011, the first Korean case of iatrogenic CJD was reported which also increased the public interest among the people [2]. So, the possibility of transfection to other persons by medical devices, operational tools or transfusion also should be considered.

On this survey about 44% of neurologists (n = 52) encountered CJD patients confirmed by biopsy or autopsy (Fig. 2) and it is very high percentage when we consider the low rate of biopsy or autopsy performance in Korea. The reason why it showed high proportion might be the overlapping patients with CJD among the respondents. Twenty-seven percent of respondents answered that CJD might occur more than 40 cases a year but 52.6% of them considered clinically diagnosed CJD would be less than 20 cases, so most neurologists recognized the number of real occurrence of CJD is larger than that of clinically diagnosed cases in Korea. Actually, according to the reports of KCDC, about 30 cases of sporadic CJD have been reported since 2008 annually but estimated occurrence rate of CJD is more than 50 to 60 cases a year in Korea [3]. We do not know the real number of CJD cases because the definite diagnosis of CJD is very rare, and possible diagnosis seems not so valid in Korea. Large proportion of Kore-

an neurologists regarded the incidence as lower than that of calculated incidence. About 62% of the neurologists on this survey had experience of caring CJD patients personally. When we added the number of respondents who just observed CJD patient diagnosed in their hospital although they did not care personally, 77.4% of neurologists had experienced CJD patient directly or indirectly. So, most of the Korean neurologists who participated in the survey had experience of CJD although it is very rare disease.

Rapidly progressive dementia and myoclonus would be the main clinical signs of sporadic CJD [4]. On this survey, 86.5% of respondents answered that rapidly progressive dementia would be the most important clinical sign and 10.5% of respondents replied myoclonus would be. Question about the order of clinical usefulness as diagnostic tool was as follows - clinical signs, CSF 14-3-3 protein, brain MRI, gene test and EEG in order. Among them, brain MRI was not included in revised 1998 diagnostic criteria of World Health organization for sCJD but it is currently modified to incorporate MRI feature [5, 6]. Brain MRI showed higher sensitivity and specificity (96% and 93% respectively) in diagnosis of CJD [7] over CSF 14-3-3 protein (sensitivity 86%, specificity 68%)[8] or EEG (sensitivity 64%, specificity 91%)[9]. Regarding question asking diagnostic specificity of each tool on the basis of 95% specificity, most of the neurologists answered that any positive finding of them would be found in other diseases too. So lack of definite diagnostic tool could be one of the causes of increasing difficulty in the diagnosis of CJD in clinical setting. CSF 14-3-3 protein shows low specificity because it can reveal false positive results in other disease such as herpes simplex encephalitis, hypoxic brain damage, brain metastasis, paraneoplastic syndrome or metabolic syndrome [10]. So other CSF markers such as tau protein or S100b protein are used combined with CSF 14-3-3 protein in some laboratories of other countries [11]. By using cell culture of neurons and glial cells, it is suggested that CSF 14-3-3 protein is just a marker of injured brain tissue rather than that of CJD [12]. The annual number of suspected CJD patients referred to KCDC is increasing constantly from 51 cases in 2008 to 91 cases in 2010. The positive ratio of CSF 14-3-3 protein among referred cases is more than 50% [3]. About 50% of them who showed CSF 14-3-3 positivity are reported as CJD in Korea.

Final diagnosis of other cases who showed CSF 14-3-3 protein positive are composed of infectious disease (43%), toxic-metabolic disease (23%), epileptic disorder (10%), tumor (7%) and others (15%) (in submission) . This was in accordance with the result of answers from neurologists who estimated positive predictive value of CSF 14-3-3 protein was from 40 to 59%. When positive finding of CSF 14-3-3 protein is combined with rapidly progressive dementia, 31.6% of respondents answered that the possibility of CJD would be about 60 to 79%. If myoclonus is added to them 40.8% of neurologists regarded the possibility of CJD would increase as high as 80 to 100%. So, rapid progressive dementia, myoclonus and CSF 14-3-3 protein play major role in the diagnosis of CJD in Korean clinical setting. Many neurologists (44%) were not confident in the diagnosis of CJD and it was more evident in residents (62.7%) than specialists (31.7%). Two main problems of this diffidence might be due to the lack of clinical experiences because CJD is rare disease (51.9%) and it showed non-specific initial clinical findings (45.1%). So it suggested that there is in need of educational programs to relieve these problems especially for residents. Many neurologists (35%) would transfer CJD suspected patient to other superior hospital for further evaluation or second opinion. This result might be derived from the burden of confirmative diagnosis as CJD which is fatal disease without cure and from difficulties in differential diagnosis because of its variable initial clinical presentations. The most common first sign was reported as cognitive decline such as deficit in attention, memory or judgment [13]. In addition to it, emotional and behavioral change, sleep disorder are also common. Myoclonus, which is especially induced by startling stimulus, might be observed 90% of cases in the course of disease progression. Extrapyramidal symptoms such as hypokinesia or cerebellar symptoms such as nystagmus, ataxia could be found in two thirds of the patients and 20 to 40% of cases showed them as main symptoms [13]. For example, it was reported that iatrogenic CJD has a tendency of presenting cerebellar symptoms in the early stage of disease [14]. Pyramidal signs such as increased deep tendon reflex or positive Babinski sign can be found in 40-80% of patients. After following up 52 cases of young sCJD patients aged less than 50 years old, it was reported that psychiatric symptoms could be easily found as it

is observed in variant CJD [15]. And there are some subtypes or variant form of CJD regarding main focal neurologic signs. Heidenhain variant CJD which present visual symptoms at first and Oppenheimer-Brownell variant CJD which shows mainly cerebellar symptoms could be examples of them.

About 85 to 90% of neurologists on this survey replied that they know well or know a little at least about sCJD, iCJD, fCJD, and vCJD. On the other hand, regarding Heidenhain variant CJD, PSPr (Proteinase sensitive prionopathy)/VPSP (Variably PSPr), Gerstmann-Strausler-Scheinker syndrome (GSS), fatal familial insomnia (FFI), sporadic fatal insomnia and 6 molecular subtypes of sCJD, large proportion of them answered that they did not know about those disease entity (76.7%, 53.4%, 60.2%, 50.4%, 63.2%, 58.6% respectively). So, it revealed the necessity of education afterward regarding those rare form of prion diseases. Regarding 6 molecular subtypes of sCJD, one of the possible reasons that it showed low recognition rate among Korean neurologists might be due to low incidence of brain biopsy or autopsy performance because molecular subtype is decided by those studies. In Korea, case of vCJD has never been reported but it was in the center of great social issues across the nation related to import of beef from U.S. in 2008. However, 40 neurologists (30%) believed that vCJD had been reported in Korea and 27 neurologists (20.3%) answered that they didn't know whether it was reported or not. About half of them are specialist working in university hospital. Eleven neurologists answered that there had not been sCJD in Korea or they did not know whether it occurred or not, although 9 of them are residents of university hospital in Seoul. Some of respondents (18.8%) have used the term "human mad cow disease" to explain sCJD and 36.8% of neurologists answered that this term could be usable although they know it is not proper. These results show possibilities of evoking social problems. In Korea, "human mad cow disease" means vCJD but it is not appropriate term and should be modified to other term "CJD related to mad cow disease". The proportions of neurologists who answered that they knew the diagnostic criteria of sporadic CJD suggested by WHO or National CJD surveillance Unit was very low as 19% and 9% respectively which showed low awareness of CJD diagnostic criteria.

For definite diagnosis as CJD, it is required to confirm pro-

teinase K resistant protein in Western blotting and to identify abnormal prion protein in immunohistochemistry on brain tissue. Triad of pathologic finding of CJD are neuronal cell loss, gliosis and vacuolization in the brain and spinal cord [16]. In this survey, 51.9% of neurologists answered that they would recommend brain biopsy for definite diagnosis just in case of confusion in the clinical diagnosis of CJD. On the contrary to it, 45.1% of respondent said that brain biopsy is necessary even though it is clinically certain. The brain tissue is not easily obtainable in Korea so the total number of referred brain tissue for CJD is just less than 5 (2cases in 2011, 5cases in 2010, 4cases in 2009, 2008, 2007) annually so, the number of actual brain biopsy is too small compared with the need of neurological specialists. Contradictory realization about brain biopsy or autopsy in Korea may contribute to the reluctant attitude to it. On top of it, surgeons also show reluctance to perform brain biopsy because of the burden of invasive procedure to this fatal transmissible disease.

Although definite diagnosis of CJD requires examination on brain tissue according to diagnostic criteria, the burden of invasive procedure described above and the possibility of false negative finding when brain tissue with no invasion is acquired also must be considered. University of California, San Francisco (UCSF) proposed diagnostic criteria of CJD based on brain MRI in 2010 [7]. Owing to the usefulness of diffusion-weighted image (DWI), they didn't recommend brain biopsy anymore in most cases of CJD patients and it is performed when it showed uncertain feature after DWI. In Korea, comparative analysis is required to evaluate which combination of diagnostic tools can be the most accurate and efficient method for diagnosis of CJD.

In summary, most of the Korean neurologists have encountered CJD although it is very rare disease. They are well recognized about the annual occurrence of CJD, sensitivity and specificity of diagnostic tools which was nearly the same with that of reported in the literature. They had difficulty in the diagnosis of CJD because of the variable initial clinical presentations in the early stage and the lack of clinical experience especially in residents. They also have some misunderstanding not only in the subtypes of CJD or diagnostic criteria but also in the vCJD which was in the center of great public interest in Korea. These suggested the necessity of educational

system for neurologists. The term "Human mad cow disease" should be reconsidered because of its potential possibilities that might evoke social problems. Although neurologists do not seem to be firmly prepared to CJD, 66.2% of them are asked about the CJD from many paramedics, doctors of other specialty or general public. Therefore considering the role of primary information providers of CJD, the educational opportunity for the neurologists seems very important to avoid the delivery of false information. About 67% of respondents also replied that they need more educational opportunity than now. Korean neurological association tried to raise the concern about CJD for neurologists through 2010 CJD symposium and it contributed somewhat to increased number of CJD suspected patients who were referred to Korea Centers For Disease Control and Prevention (KCDC) afterward [5]. This might be the good example which enhanced the concerns about CJD among the neurologists by educational symposium. The essential knowledge about CJD in clinical setting is not so much that regular small workshop for neurological resident or specialist would be adequate. Most of the neurologists are not aware of the reporting system of patients or supporting system for medical expenses, so the regular public relations also seem necessary for neurologists.

REFERENCES

1. Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation. *Geneva, Switzerland, 9-11 February 1998*.
2. Kim HL, Do JY, Cho HJ, Jeon YC, Park SJ, Ma HI, et al. *Dura mater graft-associated Creutzfeldt-Jakob disease: the first case in Korea*. *J Korean Med Sci* 2011; 26: 1515-7. *PubMed PMID: 22065911. Pubmed Central PMCID: 3207058*.
3. Current status of laboratory diagnosis for Creutzfeldt Jakob Disease [2005-2010] and introduction of the active surveillance system for CJD patients. *Public Health Weekly Report* 2011; 4: 73-80.
4. Haywood AM. *Transmissible spongiform encephalopathies*. *N Engl J Med* 1997; 337: 1821-8. *PubMed PMID: 9400041. Epub 1997/12/18. eng*.
5. National Creutzfeldt-Jakob disease Surveillance Diagnostic Criteria, 2010 : <http://www.cjd.ed.ac.kr>.
6. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, et al. *Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease*. *Brain* 2009; 132: 2659-68. *PubMed PMID: 19773352. Pubmed Central PMCID: 2759336*.
7. Vitali P, Maccagnano E, Caverzasi E, Henry RG, Haman A, Torres-Chae C, et al. *Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias*. *Neurology* 2011; 76: 1711-9. *PubMed PMID: 21471469. Pubmed Central PMCID: 3100134. Epub 2011/04/08. eng*.
8. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, et al. *Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease*. *Neurology* 2000; 55: 811-5. *PubMed PMID: 10994001. Epub 2000/09/20. eng*.
9. Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA. *Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease*. *Ann Neurol* 2004; 56: 702-8. *PubMed PMID: 15449324. Epub 2004/09/28. eng*.
10. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sanchez-Valle R, Mitrova E, et al. *CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease*. *Neurology* 2006; 67: 637-43. *PubMed PMID: 16924018. Epub 2006/08/23. eng*.
11. Satoh K, Shirabe S, Eguchi H, Tsujino A, Eguchi K, Satoh A, et al. *14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan*. *Cell Mol Biol* 2006; 26: 45-52. *PubMed PMID: 16633900. Epub 2006/04/25. eng*.
12. Satoh J, Kurohara K, Yukitake M, Kuroda Y. *The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture*. *Eur Neurol* 1999; 41: 216-25. *PubMed PMID: 10343153. Epub 1999/05/27. eng*.
13. Rabinovici GD, Wang PN, Levin J, Cook L, Pravdin M, Davis J, et al. *First symptom in sporadic Creutzfeldt-Jakob disease*. *Neurology* 2006; 66: 286-7. *PubMed PMID: 16434680. Epub 2006/01/26. eng*.
14. Will RG. *Acquired prion disease: iatrogenic CJD, variant CJD, kuru*. *Br Med Bull* 2003; 66: 255-65. *PubMed PMID: 14522863. Epub 2003/10/03. eng*.
15. Boesenberg C, Schulz-Schaeffer WJ, Meissner B, Kallenberg K, Bartl M, Heinemann U, et al. *Clinical course in young patients with sporadic Creutzfeldt-Jakob disease*. *Ann Neurol* 2005; 58: 533-43. *PubMed PMID: 16037975. Epub 2005/07/23. eng*.
16. SangYun Kim, Hae-Kwan Cheong, Seong Soo An. *Human Prion Diseases*. *J Korean Med Assoc* 2008; 51: 1125-38.

Appendix

I. Demographics of neurologists

1. Where is your hospital?

- Seoul Busan Daegu Incheon Gwangju Daejeon Ulsan Gyeonggi-do Gangwon-do Gyeongsangnam-do
 Gyeongsangbuk-do Jeollabuk-do Chungcheongnam-do Chungcheongbuk-do Jeju-do

2. Are you specialist or resident of department of neurology?

- Specialist Resident

3. What kind of hospital are you working for?

- University hospital General hospital Secondary hospital
 Private hospital Army medical officer/Public health doctor Others _____

4. How old are you?

- 20s 30s 40s 50s 60s 70s

II. Clinical experience on CJD

1. Have you ever cared CJD suspected patients before?

- 1) I've directly cared → go to 2.
 2) I've seen diagnosed case in our hospital although I haven't directly cared → go to 3.
 3) I've never cared CJD patients → go to 3.

2. Among the patients you've cared, how many patients were confirmed by the method described below?

- 1) By brain biopsy or autopsy () cases
 2) By clinical diagnosis () cases
 3) Clinically suspected case although it was not definite because of transferring to other hospital () cases

3. How many patients of CJD would occur including non-diagnosed cases in Korea per year?

- 1) < 10 2) 10-19 3) 20-29 4) 30-39 5) ≥ 40 6) I don't know

4. How many patients of CJD would be diagnosed in Korea per year?

- 1) < 10 2) 10-19 3) 20-29 4) 30-39 5) ≥ 40 6) I don't know

III. Diagnosis

1. Are you confident in the diagnosis of CJD?

- 1) Yes. I'm confident in any cases. 2) Yes unless it is specific case. 3) No.

2. What do you think most difficult problem in the diagnosis of CJD?

- 1) Various clinical presentation in the early stage
 2) Lack of clinical experience and limited information as rare disease
 3) Others: _____

3. What do you think the most important clinical sign or symptom is in the diagnosis of CJD patient?

- 1) myoclonus 2) rapid progressive cognitive decline 3) visual symptom 4) cerebellar symptom 5) others _____

4. Please select useful diagnostic tools in order of importance among items suggested as examples

< Examples >

- ① Clinical findings ② Brain MRI (including diffusion weighted image) ③ CSF 14-3-3 protein ④ EEG
 ⑤ Gene test (PRNP mutation or codon 129 type) ⑥ Others: _____

- ↳ 1st: ① ② ③ ④ ⑤ ⑥
 ↳ 2nd: ① ② ③ ④ ⑤ ⑥
 ↳ 3rd: ① ② ③ ④ ⑤ ⑥
 ↳ 4th: ① ② ③ ④ ⑤ ⑥
 ↳ 5th: ① ② ③ ④ ⑤ ⑥
 ↳ 6th: ① ② ③ ④ ⑤ ⑥

5. What do you think about the possibility of CJD when patient show rapidly progressive dementia, myoclonus and positive 4-3-3 protein in CSF?
 1) < 20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don't know

6. What do you think about the possibility of CJD when patient show rapidly progressive dementia and positive 4-3-3 protein in CSF?
 1) < 20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don't know

7. What do you think about 14-3-3 protein in CSF regarding CJD?
 1) It is always positive in CJD patients
 2) It can be negative in CJD patients although it is rare
 3) Initially it could be negative but it would be converted into positive in the course of disease eventually
 4) I don't know

8. How many patients would be diagnosed as CJD among the patients who revealed positivity in 14-3-3 protein of CSF in Korea?
 1) < 20% 2) 20-39% 3) 40-59% 4) 60-79% 5) 80-100% 6) I don't know

9. What is your opinion about the specificity of diagnostic tools below?

Ddiagnostic tools	It is found only in CJD (more than 95%)	It can be found in other diseases	I don't know
Rapidly progressed dementia & myoclonus			
Specific brain MRI finding (compatible with CJD)			
CSF 14-3-3 protein positive			
EEG periodic sharp wave complex (compatible with CJD)			

10. Do you think brain biopsy or autopsy is necessary for definite diagnosis of CJD suspected patient?
 1) It is necessary although it is certain clinically.
 2) It is necessary just in case of confusion in the diagnosis of CJD
 3) It is not necessary.

11. Would you transfer your CJD suspected patient for brain biopsy if there is a specialized hospital for brain biopsy in Korea?
 1) I would definitely persuade caregiver for brain biopsy or autopsy
 2) I would transfer just in case of confusion in the diagnosis of CJD
 3) It is not necessary

12. Have you ever transferred your CJD suspected patient(s) to superior hospital for seeking definite diagnosis or second opinion?
 1) I have transferred most of the patients for second opinion
 2) I have transferred just in case of confusion in the diagnosis of CJD
 3) I haven't transferred unless caregiver wanted to remarkably

IV. Terminology and awareness

1. Do you know the terms below?

Term	Yes	I know a little	No
sCJD Sporadic Creutzfeldt-Jakob disease			
iCJD Iatrogenic Creutzfeldt-Jakob disease			
fCJD Familial Creutzfeldt-Jakob disease			
vCJD Variant Creutzfeldt-Jakob disease			
Heidenhein variant Creutzfeldt-Jakob disease			
PSPr (Proteinase sensitive prionopathy)/VPSP (Variably PSPr)			
PRNP gene			
6 subtypes of sCJD (MM1, VV1, MM2 cortical, MV2, VV2, MM2)			
WHO diagnositic criteria of sCJD			
National CJD surveillance unit criteria of sCJD			

2. Do you think the human prion disease below have ever occurred in Korea?

Term		Yes	No	I don't know
sCJD	Sporadic Creutzfeldt-Jakob disease			
iCJD	Iatrogenic Creutzfeldt-Jakob disease			
fCJD	Familial Creutzfeldt-Jakob disease			
vCJD	Variant Creutzfeldt-Jakob disease			
PSPr (Proteinase sensitive prionopathy)/VPSP (Variably PSPr)				
GSS	Gerstmann-Straussler-Scheinker Disease			
FFI	Fatal familial insomnia			
sFI	Sporadic fatal insomnia			

3. Have you ever used the term "Human mad cow disease" when you explained sporadic CJD?

- 1) Yes I have frequently
- 2) Yes I have a few times
- 3) No I haven't

4. Do you think the term "Human mad cow disease" is proper for explaining sporadic CJD?

- 1) Yes It is proper
- 2) No but it can be used.
- 3) No. It should not be used.

5. Have you ever been asked about the medical questions regarding CJD from others?

- 1) No
- 2) Yes → go to 4.

6. Who asked you about CJD?

- 1) Other neurologist
- 2) Doctors of other specialty.
- 3) Paramedics
- 4) General public

V. Educational & Reporting system

1. CJD is legally designated infectious disease of group 3. Do you know the reporting system to public health center when suspected CJD patient occurs?

- 1) yes
- 2) I've heard but don't know well.
- 3) I've never heard of it.

2. How many times have you participated in the lectures or educational programs related to CJD (or prionopathy)?

- 1) ≥ 3
- 2) 1-2
- 3) I've never participated in it.

3. Do you think educational opportunity for neurologists regarding CJD (or prionopathy) should be increased?

- 1) Yes
- 2) It is still enough.
- 3) It is not necessary any more

4. Would you participate in the educational program for CJD (or prionopathy) if it would be held in the future?

- 1) Yes
- 2) I would participate as far as circumstances permit
- 3) No.

5. Have you ever heard of the partial supporting system for medical expenses of CJD patients as rare and incurable disease?

- 1) Yes
- 2) I've heard but don't know well.
- 3) I've never heard of it.